MTOR and breast carcinoma: Nevertheless, outside patients with renal cell carcinoma, refractory mantle cell lymphoma and ER-positive/HER2-negative breast cancer when combined with hormone therapy, the antitumour activity of the first generation of mTOR inhibitors (rapalogs) has fallen short of expectations.